Bristol-Myers secures positive EU opinion for Yervoy
This article was originally published in Scrip
Following on from the FDA's broad label approval for Yervoy (ipilimumab) in March (scripintelligence.com, 28 March 2011) to treat first-line metastatic melanoma, experts on the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) are also recommending European Union approval for the treatment of patients with previously-treated unresectable or metastatic melanoma.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.